Unknown

Dataset Information

0

Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis.


ABSTRACT:

Background

This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs).

Methods

A total of 60 SLE patients, 70 RA patients and 35 HCs, who received a complete inactivated COVID-19 vaccine (Vero cells) regimen, were recruited in the current study. Serum IgG and IgM antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were determined by using chemiluminescent microparticle immunoassay (CMIA).

Results

There were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2, and the self-reported vaccination-related adverse events among SLE patients, RA patients and HCs. The inactivated COVID-19 vaccines appeared to be well-tolerated and moderately immunogenic. In addition, case-only analysis indicated that in SLE patients, the disease manifestation of rash and anti-SSA autoantibody were associated with seroprevalence of IgG antibody against SARS-CoV-2, whereas the uses of ciclosporin and leflunomide had influence on the seroprevalence of IgM antibody against SARS-CoV-2. In RA patients, rheumatoid factor (RF) appeared to be associated with the seroprevalence of IgG antibody against SARS-CoV-2.

Conclusion

Our study reveals that the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar among SLE, RA and HCs, suggesting that COVID-19 vaccine is safe and effective for SLE and RA patients to prevent from the pandemic of COVID-19.

SUBMITTER: Wang P 

PROVIDER: S-EPMC9040458 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis.

Wang Peng P   Ni Jing J   Chu Ya-Ya YY   Chen Qing-Qing QQ   Wu Guo-Cui GC   Fang Yang Y   Chen Cong C   Zhang Ruo-Di RD   Jiang Ling-Qiong LQ   Zhao Yan Y   Fang Xi X   He Jun J   Wang De-Guang DG   Wang Gui-Hong GH   Pan Hai-Feng HF  

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20220426


<h4>Background</h4>This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs).<h4>Methods</h4>A total of 60 SLE patients, 70 RA patients and 35 HCs, who received a complete inactivated COVID-19 vaccine (Vero cells) regimen, were recruited in the current study. Serum IgG and IgM antibodies against Severe Acute Respirato  ...[more]

Similar Datasets

| S-EPMC8212085 | biostudies-literature
| S-EPMC10743599 | biostudies-literature
| S-EPMC7849999 | biostudies-literature
| S-EPMC6281033 | biostudies-other
| S-EPMC2630215 | biostudies-literature
| S-EPMC9190223 | biostudies-literature
| S-EPMC6617344 | biostudies-literature
| S-EPMC8826259 | biostudies-literature
| S-EPMC3033530 | biostudies-literature
| S-EPMC10813148 | biostudies-literature